The Interaction Between Oxytocin and Serotonin

NCT ID: NCT03577457

Last Updated: 2018-07-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-01
• Study Completion Date: 2019-07-20

Brief Summary

The primary objective of this study is to identify any interaction between oxytocin and serotonin on neural and behavioral activity related to social reward and decision making by a double-blind, placebo-controlled, between-subject, pharmacological fMRI design

Detailed Description

Serotonin and oxytocin have been proved to play an important role in social reward processing and decision making in human. The aim of this study is to determine whether they interact in those essential human behaviors by a double-blind, placebo-controlled, between-subject, pharmacological fMRI design, in which 4 groups of healthy males will be administered with a random combination of nasal oxytocin (24 international units, IU) or placebo and acute tryptophan depletion (ATD, 75.2g) or placebo (a tryptophan-balanced mixture, 78.2g). The social-reward related neural activity and behavior will be assessed by a series of social reward task in and out of fMRI scanner and the decision making will be assessed by reversal learning task, ultimatum game (UG) and loss aversion task. The interaction between serotonin and oxytocin on brain networks will also be tested by resting state.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

male oxytocin and ATD group

male subjects receiving oxytocin and ATD treatment

Group Type: EXPERIMENTAL

oxytocin nasal spray

Intervention Type: DRUG

intranasal administration of oxytocin (24 IU)

ATD treatment

Intervention Type: DRUG

oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

male oxytocin and placebo group

male subjects receiving oxytocin and ATD-placebo treatment

Group Type: EXPERIMENTAL

oxytocin nasal spray

Intervention Type: DRUG

intranasal administration of oxytocin (24 IU)

oral placebo treatment (placebo-control for ATD)

Intervention Type: DRUG

oral administration of a tryptophan-balanced mixture (78.2g)

male placebo and ATD group

male subjects receiving oxytocin placebo and ATD treatment

Group Type: EXPERIMENTAL

ATD treatment

Intervention Type: DRUG

oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

intranasal placebo treatment (placebo-control for oxytocin)

Intervention Type: DRUG

intranasal administration of placebo nasal spray

male placebo group

male subjects receiving oxytocin placebo and ATD placebo treatment

Group Type: PLACEBO_COMPARATOR

intranasal placebo treatment (placebo-control for oxytocin)

Intervention Type: DRUG

intranasal administration of placebo nasal spray

oral placebo treatment (placebo-control for ATD)

Intervention Type: DRUG

oral administration of a tryptophan-balanced mixture (78.2g)

Interventions

oxytocin nasal spray

intranasal administration of oxytocin (24 IU)

Intervention Type: DRUG

ATD treatment

oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

Intervention Type: DRUG

intranasal placebo treatment (placebo-control for oxytocin)

intranasal administration of placebo nasal spray

Intervention Type: DRUG

oral placebo treatment (placebo-control for ATD)

oral administration of a tryptophan-balanced mixture (78.2g)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy subjects without past or current psychiatric or neurological disorders
• Right-handedness

Exclusion Criteria

• History of head injury;
• Medical or psychiatric illness.
• High blood pressure, general cardio-vascular alterations
• History of drug or alcohol abuse or addiction.
• Allergy against medications or general strong allergies
• Sleep disorders.
• Visual or motor impairments

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Benjamin Becker

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Beijing Normal University

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Yina Ma, Dr.

Role: CONTACT

yma@bnu.edu.cn

+86-15221877059

Other Identifiers

SANP-2017-3-ATD

Identifier Type: -

Identifier Source: org_study_id